Status:

COMPLETED

Linking Infectious and Narcology Care-Part II

Lead Sponsor:

Boston Medical Center

Collaborating Sponsors:

National Institute on Drug Abuse (NIDA)

Conditions:

HIV Infection

Drug Use

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This study, "Linking Infectious and Narcology Care - Part II (LINC-II)," will implement and evaluate a multi-faceted intervention (LINC-II), via a two-armed randomized controlled trial among 240 HIV-i...

Detailed Description

Russia and Eastern Europe continue to have one of the fastest growing HIV epidemics in the world, with highest transmission risks among people who inject drugs (PWID) and their sexual partners. While ...

Eligibility Criteria

Inclusion

  • 18 years or older
  • HIV infected
  • Hospitalized at narcology hospital
  • History of injection drug use
  • Current diagnosis of opioid use disorder
  • Provision of information for 2 contacts to assist with follow-up
  • Address within 100 kilometers of St. Petersburg
  • Possession of a telephone (home or cell)
  • Able and willing to comply with all study protocols and procedures

Exclusion

  • Not fluent in Russian
  • Cognitive impairment
  • Pregnancy, planning to become pregnant, or breastfeeding
  • ART use in past 30 days prior to hospitalization
  • Known hypersensitivity to naltrexone
  • Acute severe psychiatric illness (i.e. ,answered yes to any of the following: past three month active hallucinations; mental health symptoms prompting a visit to the ED or hospital; mental health medication changes due to worsening symptoms; presence of suicidal ideations)
  • Known history of liver failure
  • ALT or AST \>5 times the upper limit of normal
  • Known severe thrombocytopenia (\<50k)
  • Known coagulation disorder/taking anticoagulation medications
  • Body habitus that precludes intramuscular injection
  • Known hypersensitivity to naloxone
  • Known history of Raynaud's disease
  • Known history of Itsenko-Cushing syndrome
  • Known history of generalized mycoses
  • Known history of glaucoma
  • Known history of osteoporosis.
  • Planned surgeries in the next 12 months

Key Trial Info

Start Date :

September 19 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 6 2022

Estimated Enrollment :

225 Patients enrolled

Trial Details

Trial ID

NCT03290391

Start Date

September 19 2018

End Date

April 6 2022

Last Update

April 18 2023

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

First St. Petersburg Pavlov State Medical University

Saint Petersburg, Russia, 197022

2

City Addiction Hospital

Saint Petersburg, Russia